Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens

Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens

<p>Abstract</p> <p>Background</p> <p>Antiretrovirals used to treat HIV-infected patients have the potential to adversely affect serum lipid profiles and increase the risk of cardiovascular disease which is an emerging concern among HIV-infected patients. Since boosted a...

Full description

Bibliographic Details
Main Authors:	Tasker Sybil, Crum-Cianflone Nancy, Riddle Mark, Golub Elizabeth T, Benning Lorie, Ganesan Anuradha, Jacobson Lisa, Gange Stephen J
Format:	Article
Language:	English
Published:	BMC 2009-06-01
Series:	AIDS Research and Therapy
Online Access:	http://www.aidsrestherapy.com/content/6/1/13

Similar Items

Serum Lipid Profiles of Patients Taking Efavirenz-Based Antiretroviral Regimen Compared to Ritonavir-Boosted Atazanavir with an Optimized Background at Zewditu Memorial Hospital, Addis Ababa, Ethiopia
by: Muche Belete A, et al.
Published: (2021-02-01)

Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.
by: Takeshi Nishijima, et al.
Published: (2013-01-01)

An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
by: Eva Agnes Odongpiny Laker, et al.
Published: (2019-03-01)

Is ritonavir-boosted atazanavir a risk for cholelithiasis compared to other protease inhibitors?
by: Yohei Hamada, et al.
Published: (2013-01-01)

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
by: Spagnuolo V, et al.
Published: (2019-01-01)

Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population
by: Rusconi Stefano, et al.
Published: (2012-08-01)

Liver Profile of Atazanavir/Ritonavir in Pregnant Albino Rats
by: Elias Adikwu, et al.
Published: (2019-10-01)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
by: Tony Antoniou, et al.
Published: (2017-04-01)

Efavirenz Outperforms Boosted Atazanavir among Treatment-Naive HIV-1-Infected Persons in Routine Clinical Care
by: Toshibumi Taniguchi MD, et al.
Published: (2013-03-01)

Safety of atazanavir/ritonavir with tenofovir disoproxil fumarate in HIV-infected adolescents
by: T. Bunupuradah, et al.
Published: (2014-04-01)

Prevalence and correlates of persistent intracellular HIV transcription in individuals on efavirenz versus atazanavir-based regimens: A prospective cohort study.
by: Dimitrios Pilalas, et al.
Published: (2018-01-01)

Baseline natural killer and T cell populations correlation with virologic outcome after regimen simplification to atazanavir/ritonavir alone (ACTG 5201).
by: John E McKinnon, et al.
Published: (2014-01-01)

Development and Validation of Atazanavir and Ritonavir Determination in Human Plasma by HPLC-MS Method
by: T. N. Komarov, et al.
Published: (2020-02-01)

A population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: a study of HIV-infected Zimbabwean adolescents
by: Bernard Ngara, et al.
Published: (2020-08-01)

Prospective evaluation of bone markers, parathormone and 1,25-(OH)<sub>2 </sub>vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz
by: Focà Emanuele, et al.
Published: (2012-02-01)

Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice.
by: Pierre Gantner, et al.
Published: (2016-01-01)

Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir
by: Christiana Smith, et al.
Published: (2016-01-01)

Dyslipidaemia associated with the highly active antiretroviral therapy in aids patient: reversion after switching (stavudine to tenofovir and lopinavir/ritonavir to atazanavir/ritonavir)
by: Hamilton Domingos, et al.

Efavirenz and Lopinavir/Ritonavir Alter Cell Cycle Regulation in Lung Cancer
by: Rahaba Marima, et al.
Published: (2020-08-01)

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT
by: Ross Lisa L, et al.
Published: (2008-03-01)

Acute development of Cushing syndrome in an HIV-infected child on atazanavir/ritonavir based antiretroviral therapy
by: Gueorgui Dubrocq, et al.
Published: (2017-10-01)

Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States.
by: Anita J Brogan, et al.
Published: (2018-01-01)

HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells.
by: Martine Auclair, et al.
Published: (2020-01-01)

Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia.
by: Rudolph L Gleason, et al.
Published: (2015-01-01)

Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study.
by: Asita Wongprikorn, et al.
Published: (2016-01-01)

Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world.
by: Emanuela Foglia, et al.
Published: (2013-01-01)

Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir.
by: Joshua A Beckman, et al.
Published: (2017-01-01)

Correction: Cost-Utility Analysis of Lopinavir/Ritonavir versus Atazanavir + Ritonavir Administered as First-Line Therapy for the Treatment of HIV Infection in Italy: From Randomised Trial to Real World
by: Emanuela Foglia, et al.
Published: (2014-01-01)

Correction: Cost-Utility Analysis of Lopinavir/Ritonavir versus Atazanavir + Ritonavir Administered as First-Line Therapy for the Treatment of HIV Infection in Italy: From Randomised Trial to Real World.
by: Emanuela Foglia, et al.
Published: (2014-01-01)

Clinically relevant enantiomer specific R‐ and S‐praziquantel pharmacokinetic drug‐drug interactions with efavirenz and ritonavir
by: Chenai Sheilla Mutiti, et al.
Published: (2021-05-01)

Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial
by: Restelli U, et al.
Published: (2017-03-01)

Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks
by: Squires KE, et al.
Published: (2017-03-01)

Validation of Simultaneous Quantitative Method of HIV Protease Inhibitors Atazanavir, Darunavir and Ritonavir in Human Plasma by UPLC-MS/MS
by: Tulsidas Mishra, et al.
Published: (2014-01-01)

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)
by: Lucia Taramasso, et al.
Published: (2018-07-01)

Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial
by: Restelli U, et al.
Published: (2017-09-01)

Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial [Corrigendum]
by: Restelli U, et al.
Published: (2017-04-01)

Boosting the Brain Delivery of Atazanavir through Nanostructured Lipid Carrier-Based Approach for Mitigating NeuroAIDS
by: Saif Ahmad Khan, et al.
Published: (2020-11-01)

Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients
by: Catherine Orrell, et al.
Published: (2015-01-01)

Antenatal Atazanavir: A Retrospective Analysis of Pregnancies Exposed to Atazanavir
by: Miriam Samuel, et al.
Published: (2014-01-01)

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens.
by: Luis F López-Cortés, et al.
Published: (2016-01-01)

Cannot write session to /tmp/vufind_sessions/sess_596qjvsnjv437h957f69q40i0c